What is Arvinas Therapeutics market cap?
Arvinas Therapeutics, a biotech company specializing in PROTAC protein degradation technology, has a market capitalization of around $20 billion as of its listing on Nasdaq in 2018. The company's market cap could potentially increase significantly in the future based on the progress of its clinical pipelines and the commercialization of its PROTAC-based therapies.